Graft-versus-Leukemia Reactions in Clinical Bone Marrow Transplantation

References

• Working Party on Leukaemia, European Group for Bone Marrow Transplantation. Allogeneic bone marrow transplantation for leukaemia in Europe. Lancet 1988; i: 1379–1382
   Google Scholar
• Bearman S. I., Appelbaum F. R., Buckner C. D., Peter-sen F. B., Fisher L. D., Clift R. A., Thomas E. D. Regimen-related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol. 1988; 6: 1562–1568
   PubMed Web of Science ®Google Scholar
• Odom L. F., August C. S., Githens J. H., Humbert J. R., Morse H., Peakman D., Sharma B., Rusnak S. L., Johnson F. B. Remission of relapsed leukaemia during a graft-versus-host reaction: A “graft-versus leukaemia” reaction in man?. Lancet 1978; ii: 537–540
   Google Scholar
• Weiden P. L., Flournoy N., Thomas E. D., Prentice R., Fefer A., Buckner C. D., Storb R. Antileu-kemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 1979; 300: 1068–1073
   PubMed Web of Science ®Google Scholar
• Weiden P. L., Sullivan K. M., Flournoy N., Storb R., Thomas E. D. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med. 1981; 304: 1529–1533
   PubMed Web of Science ®Google Scholar
• Fefer A., Sullivan K. M., Weiden P., Buckner C. D., Schoch G., Storb R., Thomas E. D. Graft versus leukemia effect in man: the relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation. Prog. Clin. Biol. Res. 1987; 244: 401–408
   PubMedGoogle Scholar
• Gale R. P., Goldman J. M., Horowitz M. M. Bone marrow transplants in twins with chronic myelogenous leukemia. Blood 1991; 78(Suppl 1)244a
   Google Scholar
• Kersey J. H., Weisdorf D., Nesbit M. E., LeBien T. W., Woods W. G., McGlave P. B., Kim T., Vallera D. A., Goldman A. I., Bostrom B. Comparison of au-tologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N. Engl. J. Med. 1987; 317: 461–467
   PubMed Web of Science ®Google Scholar
• Apperley J. F., Jones L., Hale G., Waldmann H., Hows J., Rombos Y., Tsatalas C., Marcus R. E., Goolden A. W., Gordon Smith E. C. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-I reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986; 1: 53–66
   PubMed Web of Science ®Google Scholar
• Bacigalupo A., Van Lint M. T., Occhini D., Gualandi F., Lamparelli T., Sogno G., Tedone E., Frassoni F., Tong J., Marmont A. M. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423–1428
   PubMed Web of Science ®Google Scholar
• Gajewski J. L., Ho W. G., Feig S. A., Hunt L., Kaufman N., Champlin R. E. Bone marrow transplantation using unrelated donors for patients with advanced leukemia or bone marrow failure. Transplantation 1990; 50: 244–249
   PubMed Web of Science ®Google Scholar
• Horowitz M. M., Gale R. P., Sondel P. M., Goldman J. M., Kersey J., Kolb H. J., Rimm A. A., Ringden O., Rozman C., Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555–562
   PubMed Web of Science ®Google Scholar
• Oshimi K., Oshimi Y., Akutsu M., Takei Y., Saito H., Okada M., Mizoguchi H. Cytotoxicity of inter-leukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938–948
   PubMed Web of Science ®Google Scholar
• Gorin N. C. Autologous bone marrow transplantation in hematological malignancies. Am. J. Clin. Oncol. 1991; 14(Suppl 1)S5–S14
   PubMed Web of Science ®Google Scholar
• Slavin S., Ackerstein A., Naparstek E., Or R., Weiss L. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?. Bone Marrow Transplant. 1990; 6: 155–161
   PubMed Web of Science ®Google Scholar
• Brenner M. K., Heslop H. E. Immunotherapy of leukemia. Leukemia 1992; 6 (Suppl 1): 76–79
   PubMed Web of Science ®Google Scholar
• Sullivan K. M., Weiden P. L., Storb R., Witherspoon R. P., Fefer A., Fisher L., Buckner C. D., Anaselti C., Appelbaum F. R., Badger C. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA- identical siblings as treatment of acute and chronic leukemia. Blood 1989; 73: 1720–1728
   PubMed Web of Science ®Google Scholar
• Champlin R., Jansen J., Ho W., Gajewski J., Nimer S., Lee K., Territo M., Winston D., Tricot G., Reichert T. Retention of graft-versus-leukemia using selective depletion of CD8-positive T lymphocytes for prevention of graft-versus-host disease following bone marrow transplantation for chronic myelogenous leukemia. Transplant. Proc 1991; 23: 1695–1696
   PubMed Web of Science ®Google Scholar
• Cullis J. O., Jiang Y. Z., Schwarer A. P., Hughes T. P., Barrett A. J., Goldman J. M. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379–1381
   PubMed Web of Science ®Google Scholar
• Mackinnon S., Hows J. M., Goldman J. M. Induction of in vitro graft-versus-leukemia activity following bone marrow transplantation for chronic myeloid leukemia. Blood 1990; 76: 2037–2045
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H. J., Pepe M., Appelbaum F., Anasetti C., Beany P., Bensinger W., Berenson R., Buckner C. D., Clift R. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729–1734
   PubMed Web of Science ®Google Scholar
• International Bone Marrow Transplant Registry. Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. Lancet 1989; i: 535–537
   Google Scholar
• Elfenbein G., Graham-Pole J., Weiner R., Goedert G., Gross S. Consequences of no prophylaxis for acutegraft-versus-host disease after HLA-identical bone marrow transplantation. Blood 1987; 70(Suppl 1)305a
   Google Scholar
• Bortin M. M., Rimm A. A., Saltzstein E. C., Rodey G. E. Graft versus leukemia. HI. Apparent independent antihost and antileukemic activity of transplanted im-munocompetent cells. Transplantation 1973; 16: 182–188
   PubMed Web of Science ®Google Scholar
• Bortin M. M., Truitt R. L., Rimm A. A., Bach F. H. Graft-versus-leukemia reactivity induced by alloim-munization without augmentation of graft-versus-host reactivity. Nature 1979; 281: 490–491
   PubMed Web of Science ®Google Scholar
• Moscovitch M., Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. J. Immunol. 1984; 132: 997–1000
   PubMed Web of Science ®Google Scholar
• Lefever A. V., Truitt R. L., Shih C-Y. Reactivity of in vitro expanded alloimmune cytotoxic T lymphocytes and Qa-1 specific cytotoxic T lymphocytes against AKR leukemia in vivo. Transplantation 1985; 40: 531–537
   PubMed Web of Science ®Google Scholar
• Weiss L., Weigensberg M., Morecki S., Bar S., Cobbold S., Waldmann H., Slavin S. Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia. Cancer Immunol, lmmunother. 1990; 31: 236–242
   PubMed Web of Science ®Google Scholar
• Sosman J. A., Oettel K. R., Smith S. D., Hank J. A., Fisch P., Sondel P. M. Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleu-kemic cells. Blood 1990; 75: 2005–2016
   PubMed Web of Science ®Google Scholar
• Komgold R., Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335–339
   PubMed Web of Science ®Google Scholar
• Champlin R., Ho W., Gajewski J., Feig S., Burnison M., Holley G., Greenberg P., Lee K., Schmid I., Giorgi J. Selective depletion of CD8+ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation. Blood 1990; 76: 418–423
   PubMed Web of Science ®Google Scholar
• Waldmann H., Polliack A., Hale G., Or R., Cividalli G., Weiss L., Weshler Z., Samuel S., Manor D., Braut-bar C. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; ii: 483–486
   Google Scholar
• Schattenberg A., De Witte T., Preijers F., Raemaekers J., Muus P., Van der Lely N., Boezeman J., Wessels J., Van Dijk B., Hoogenhout J. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation. Blood 1990; 75: 1356–1363
   PubMed Web of Science ®Google Scholar
• Talbot D. C., Powles R. L., Sloane J. P., Rose J., Tre-leaven J., Aboud H., Helenglass G., Parikh P., Smith C., Rowley M. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukaemia. Bone Marrow Transplant. 1990; 6: 17–20
   PubMed Web of Science ®Google Scholar
• Carella A. M., Gaozza E., Raffo M. R., Carlier P., Fras-soni F., Valbonesi M., Lercari G., Sessarego M., Def-ferrari R., Guerrasio A. Therapy of acute phase chronic myelogenous leukemia with intensive chemotherapy, blood cell autotransplant and cyclosporine A. Leukemia 1991; 5: 517–521
   PubMed Web of Science ®Google Scholar
• Blaise D., Olive D., Stoppa A. M., Viens P., Pourreau C., Lopez M., Attal M., Jasmin C., Monges G., Ma-was C. Hématologie and immunologie effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990; 76: 1092–1097
   PubMed Web of Science ®Google Scholar
• Nagler A., Ackerstein A., Or R., Drakos P., Kapelushnik Y., Mehta J., Naparstek E., Slavin S. Adoptive immunotherapy with mismatched allogeneic peripheral blood lymphocytes (PBL) following autologous bone marrow transplantation (ABMT). Exp. Hematol. 1992; 20: 705
   Web of Science ®Google Scholar
• Bengtsson M., Simonsson B., Carlsson K., Nilsson B., Smedmyr B., Termander B., Oberg G., Totterman T. H. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator Linomide after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992; 53: 882–888
   PubMed Web of Science ®Google Scholar
• Agah R., Malloy B., Kerner M., Mazumder A. Generation and characterization of IL-2-activated bone marrow cells as a potent graft vs tumor effector in transplantation. J. Immunol. 1989; 143: 3093–3099
   PubMed Web of Science ®Google Scholar
• Sykes M., Romick M. L., Sachs D. H. Inter-leukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells. Proc. Nat. Acad. Sci. USA 1990; 87: 5633–5637
   PubMed Web of Science ®Google Scholar